



Markets
/
Stocks
/
nasdaq-azn
/

AstraZeneca PLC

AZN

View Detailed Chart

69.570USD

+0.019+0.03%

Close 04/25, 16:00（ET）Quotes delayed by 15 min

215.74BMarket Cap

30.67P/E TTM



AstraZeneca PLC

69.570

+0.019+0.03%

Company

Intraday

30m

Today

+0.03%

5 Days

+2.93%

1 Month

-4.33%

6 Months

-7.30%

Year to Date

+6.18%

1 Year

-7.45%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 13 analysts

BUY

Current Rating

99.860

Target Price

43.54%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

160

Total

Median

Average

Company name

Ratings

Analysts

AstraZeneca PLC

AZN

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(2)

Buy(4)

Indicators

Sell(1)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.824

Neutral

RSI(14)

49.068

Neutral

STOCH(KDJ)(9,3,3)

92.121

Overbought

ATR(14)

2.194

Low Volatility

CCI(14)

121.142

Buy

Williams %R

2.573

Overbought

TRIX(12,20)

-0.396

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

68.480

Buy

MA10

67.921

Buy

MA20

68.801

Buy

MA50

72.800

Sell

MA100

70.357

Sell

MA200

73.759

Sell

News

AstraZeneca breast cancer drug shows positive results, shares up

Investing.com -- AstraZeneca (NASDAQ:AZN) announced on Wednesday that its experimental breast cancer treatment, camizestrant, helped extend survival without disease progression in patients with an advanced form of the illness during a late-stage clinical trial.

Investing.comWed, Feb 26

AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal

Feb 20 (Reuters) - AstraZeneca AZN.L will buy longtime partner FibroGen's FGEN.O China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world's second-biggest economy.

ReutersThu, Feb 20

Company

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

Company codeAZN

CompanyAstraZeneca PLC

CEOMr. Marc Dunoyer

Websitehttps://www.astrazeneca.com/